GrifolsGRFS +2.08%84 Market Cap is $5,006 Mil as of Jun. 25, 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.79 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Grifols ranks better than 93.16% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Grifols's share price for the quarter that ended in Mar. 2026 was $8.02. Grifols's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 681 Mil. Therefore, Grifols's market cap for the quarter that ended in Mar. 2026 was $5,458 Mil.
Grifols's quarterly market cap
declined
from Sep. 2025 ($6,778 Mil) to Dec. 2025 ($6,363 Mil) and
declined
from Dec. 2025 ($6,363 Mil) to Mar. 2026 ($5,458 Mil).
Grifols's annual market cap
declined
from Dec. 2023 ($7,850 Mil) to Dec. 2024 ($5,062 Mil) but then
increased
from Dec. 2024 ($5,062 Mil) to Dec. 2025 ($6,363 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Grifols's Enterprise Value for Today is $18,097 Mil.
Grifols (NAS:GRFS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Grifols Market Cap Related Terms
Grifols Market Cap Historical Data
* Premium members only.
The historical data trend for Grifols's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Grifols's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Market Cap distribution charts can be found below:
* The bar in red indicates where Grifols's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Grifols's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (GRFS) has a Market Cap of $5,006 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Grifols and its competitors. According to the industry distribution chart, Grifols ranks #70 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 6.8%.
Is Grifols' Market Cap too high?
Grifols' current Market Cap is $5,006 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Grifols' value of $5,006 Mil is 2324.2% above this industry median. Based on the distribution chart, Grifols ranks #70 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #70 out of 1023 companies for Market Cap. This places Grifols in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.50. Grifols' value of $5,006 Mil is 2324.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Market Cap of $5,006 Mil is 2324.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Market Cap is $5,006 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.79, compared to a current price of $7.36 — trading 16.3% below its estimated fair value. The current Market Cap is $5,006 Mil and 2324.2% above the Drug Manufacturers industry median of 206.50. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Grifols (GRFS), the current Market Cap is $5,006 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.36 is trading 16.3% below its estimated GF Value™ of $8.79.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
Market Cap: $5,006 Mil
GF Value™: $8.79 vs. price of $7.36 (16.3% below fair value)
Industry Position: 2324.2% above the Drug Manufacturers median (#70 of 1023)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score
Get the complete analysis for GRFS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
